Article Details
Retrieved on: 2024-11-16 15:46:38
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses a new CRISPR/Cas9 gene-editing therapy developed by Intellia Therapeutics for transthyretin amyloidosis, addressing the amyloid deposits that cause heart failure. This technological advancement offers potential improvements for amyloidosis patients.
Article found on: www.royalfree.nhs.uk
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here